concomitant H1 antihistamines and EGFR-TKIs in NSCLC

Concomitant H1 Antihistamines and EGFR-TKIs in NSCLC

Overview

Target Group:

• patients with advanced (Stage III/IV) Non-Small Cell Lung Cancer (NSCLC) receiving Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) therapy (e.g., Gefitinib, Erlotinib, Afatinib, Osimertinib)

Core Question:

• does the concomitant prescription of H1 antihistamines (H1AHs) improve time to treatment failure (TTF) and reduce all-cause mortality in EGFR-TKI-treated patients?

Key Findings

Reduced Treatment Failure:

• concomitant H1AH prescriptions ( days) were independently associated with a significantly lower risk of treatment failure compared to non-H1AH use (aHR 0.61; 95% CI 0.53–0.71)
• mean TTF was extended to 2.09 years vs. 1.25 years

Lower Mortality:

• concomitant H1AH use was linked to a 64% reduction in all-cause mortality (aHR 0.36; 95% CI 0.30–0.44)

Duration-Dependent Effect:

• extended prescription durations demonstrated greater clinical benefit
• days exposure: TTF aHR 0.58; Mortality aHR 0.35
• days exposure: TTF aHR 0.58; Mortality aHR 0.33

First-Year Impact:

• the benefit was highest within the first year (NNT = 3.85 to prevent one treatment failure)

Subgroup & Sensitivity Highlights

Consistency:

• benefits persisted across age groups (most pronounced in patients years), smoking statuses, BMI categories, and disease stages (Stage III/IV)

EGFR Mutation Status:

• favourable outcomes were consistent in EGFR mutation-positive patients, including Exon 19 (aHR 0.60), Exon 20 (aHR 0.51), and Exon 21 (aHR 0.65) mutations

TKI Subtypes:

• benefits were noted across first- and second-generation EGFR-TKIs, with the strongest effect observed with Afatinib (aHR 0.46)

Proposed Mechanisms

1. Bypass Signaling Blockade:

• blockade of the histamine H1 receptor (encoded by HRH1) inhibits protein kinase C-mediated activation of MAPK and PI3K/AKT pathways, suppressing tumour proliferation and angiogenesis

1. STAT3 Inactivation:

• cationic amphiphilic antihistamines elevate lysosomal pH, leading to cytosolic acidification and STAT3 inactivation (a key driver of TKI resistance)

1. Tumour Microenvironment:

• H1AHs reduce M2-like macrophage polarization and immune-checkpoint upregulation, helping restore antitumor T-cell activity

1. Adherence & Toxicity:

• mitigates drug-induced allergic/hypersensitivity reactions and skin toxicities associated with EGFR-TKIs, enhancing patient compliance

Clinical Practice Takeaways

Potential Drug Repurposing:

• H1AHs are low-cost, widely available, and safe agents that may serve as a simple adjunctive strategy to delay TKI resistance

Caution:

• these observational RWE findings are hypothesis-generating
• prospective clinical trials are needed before routine prescribing solely for oncological benefit can be universally recommended

Reference:

• Nguyen VT, Le NH, Phan NQ, et al. The potential impact of H1 antihistamines on clinical outcomes in NSCLC patients undergoing EGFR-TKIs treatment. Br J Clin Pharmacol. 2026; 1-13.